XML 52 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Quarterly Financial Information (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]  
Schedule of quarterly financial information (unaudited)
The following is a summary of the quarterly results of operations of the Company for the years ended December 31, 2017 and 2016 (unaudited):
 
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
December 31,
2017
 
September 30,
2017
 
June 30,
2017
 
March 31,
2017
Consolidated Statements of Operations:
 
 
 
 
 
 
 
Revenue:
 
 
 
 
 
 
 
Revenue under collaborative research and development arrangements
$
7,409,214

 
$
351,272

 
$
16,358,316

 
$
4,288,586

Revenue under collaborative research and development arrangements with affiliated entity
226,486

 
129,133

 
176,879

 
233,330

Grants and miscellaneous revenue
980,443

 
1,456,216

 
2,797,647

 
5,240,233

Grants and miscellaneous revenue from affiliated entity
171,091

 
707,922

 
1,079,282

 
614,036

Total revenues
8,787,234

 
2,644,543

 
20,412,124

 
10,376,185

Operating Expenses:
 
 
 
 
 
 
 
Research and development
24,641,124

 
25,510,239

 
23,878,751

 
24,542,504

General and administrative
8,033,899

 
6,319,775

 
6,169,106

 
7,767,589

Gain on sale of assets
(1,000,000
)
 
—

 
—

 
—

Total operating expenses
31,675,023

 
31,830,014

 
30,047,857

 
32,310,093

Loss from operations
(22,887,789
)
 
(29,185,471
)
 
(9,635,733
)
 
(21,933,908
)
Interest and other income, net
509,266

 
463,346

 
300,021

 
340,341

Change in fair value of common stock warrants
579,546

 
423,296

 
(312,500
)
 
116,477

Gain (Loss) from investment in affiliated entity
292,798

 
(5,835,741
)
 
169,096

 
(1,608,817
)
Net loss attributable to Inovio Pharmaceuticals, Inc.
$
(21,506,179
)
 
$
(34,134,570
)
 
$
(9,479,116
)
 
$
(23,085,907
)
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders
 
 
 
 
 
 
 
Basic
$
(0.24
)
 
$
(0.39
)
 
$
(0.13
)
 
$
(0.31
)
Diluted
$
(0.24
)
 
$
(0.40
)
 
$
(0.13
)
 
$
(0.31
)


 
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
December 31,
2016
 
September 30,
2016
 
June 30,
2016
 
March 31,
2016
Consolidated Statements of Operations:
 
 
 
 
 
 
 
Revenue:
 
 
 
 
 
 
 
Revenue under collaborative research and development arrangements
$
476,586

 
$
2,327,316

 
$
1,889,988

 
$
1,796,857

Revenue under collaborative research and development arrangements with affiliated entity
189,278

 
574,596

 
499,720

 
137,000

Grants and miscellaneous revenue
7,735,428

 
9,410,648

 
3,814,083

 
6,176,298

Grants and miscellaneous revenue from affiliated entity
112,660

 
227,903

 
—

 
—

Total revenues
8,513,952

 
12,540,463

 
6,203,791

 
8,110,155

Operating Expenses:
 
 
 
 
 
 
 
Research and development
23,911,731

 
26,980,343

 
19,630,801

 
18,189,160

General and administrative
6,965,517

 
5,755,603

 
5,799,530

 
5,371,613

Gain on sale of assets
—

 
—

 
(1,000,000
)
 
—

Total operating expenses
30,877,248

 
32,735,946

 
24,430,331

 
23,560,773

Loss from operations
(22,363,296
)
 
(20,195,483
)
 
(18,226,540
)
 
(15,450,618
)
Interest and other income, net
191,460

 
391,596

 
341,131

 
333,070

Change in fair value of common stock warrants
644,888

 
2,690

 
(113,775
)
 
(406,249
)
Gain (Loss) from investment in affiliated entity
(4,706,522
)
 
(958,141
)
 
(705,527
)
 
7,480,977

Net loss attributable to Inovio Pharmaceuticals, Inc.
$
(26,233,470
)
 
$
(20,759,338
)
 
$
(18,704,711
)
 
$
(8,042,820
)
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders
 
 
 
 
 
 
 
          Basic
$
(0.35
)
 
$
(0.28
)
 
$
(0.26
)
 
$
(0.11
)
          Diluted
$
(0.36
)
 
$
(0.28
)
 
$
(0.26
)
 
$
(0.11
)